research compound raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-13 and is reviewed periodically as new material appears.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Enterochromaffin-like cells or ECL cells are a type of neuroendocrine cell found in the gastric glands of the gastric mucosa beneath the epithelium, in particular in the vicinity of parietal cells, that aid in the production of gastric acid via the release of histamine. They are also considered a type of enteroendocrine cell.
=== James: The Boss's Son === First aired: Online James bullies fellow co-worker Sean. The only problem is that James is the boss's son. Ben Lagman submits James three times in the first round, but James survives the second round, despite taking quite a beating. This was Ben Lagman's first and, so far, only appearance in the series. The episode did not air in regular chronology and is not available on the Bully Beatdown website like most other episodes. It has been leaked on to the internet and it is unknown why the episode was not aired in the regular time slot. This episode has aired, late nights on MTV2.
== External links == Anatomy photo: nervous/pns/nerve1/nerve1 - Comparative Organology at University of California, Davis - "PNS, nerve (LM, Low)" Anatomy photo: nervous/pns/nerve2/nerve1 - Comparative Organology at University of California, Davis - "PNS, nerve (LM, Medium)" Diagram at Howard
Thalidomide Cytokine antagonists Cannabinoids Omega-3 fatty acids, including eicosapentaenoic acid (EPA) Non-steroidal anti-inflammatory drugs Prokinetics Ghrelin and ghrelin receptor agonist Anabolic catabolic transforming agents such as MT-102 Selective androgen receptor modulators Cyproheptadine Hydrazine sulfate Medical marijuana has been allowed for the treatment of cachexia in some US states, such as Missouri, Illinois, Maryland, Delaware, Nevada, Michigan, Washington, Oregon, California, Colorado, New Mexico, Arizona, Vermont, New Jersey, Rhode Island, Maine, and New York Hawaii and Connecticut.
A bacteriologist is a microbiologist or other trained professional in bacteriology. Bacteriologists are interested in studying and learning about bacteria, as well as using their skills in clinical settings. This includes investigating properties of bacteria such as morphology, ecology, genetics and biochemistry, phylogenetics, genomics and many other areas related to bacteria like disease diagnostic testing. They can also work as medical scientists, veterinary scientists, or diagnostic technicians in locations like clinics, blood banks, hospitals, laboratories and animal hospitals. Bacteriologists working in public health or biomedical research help develop vaccines for public use.
Sources: en.wikipedia.org
== Cracked heels == Cracked heels is a common health problem and it may cause diseases and infections. It is caused by dryness of the foot skin, and accumulation of dead skin. Over time, it may cause pain and irritations. Various moisturising creams and foot files are available to cure and prevent it.
== Epidemiology == BPD has a point prevalence of 1.6% and a lifetime prevalence of 5.9% of the global population. Within clinical settings, the occurrence of BPD is 6.4% among urban primary care patients, 9.3% among psychiatric outpatients, and approximately 20% among psychiatric inpatients. Utilization of healthcare resources by individuals with BPD is high. Up to half may show significant improvement in their condition, resulting in ineligibility for diagnosis of BPD, following a ten-year period with appropriate treatment. Regarding gender distribution, women are diagnosed with BPD three times more frequently than men in clinical environments. Nonetheless, epidemiological research in the United States indicates no significant gender difference in the lifetime prevalence of BPD within the general population. Feminist scholars argue that the diagnosis is disproportionately applied to women, particularly survivors of childhood sexual abuse, and that it pathologizes the understandable emotional and relational responses to gendered violence. The relationship between BPD and ethnicity continues to be ambiguous, with divergent findings reported in the United States. The overall prevalence of BPD in the U.S. prison population is thought to be 17%. Sexual minorities (i.e., lesbian, gay, bisexual) are up to 3.82 times more likely to be diagnosed with BPD and gender minorities (i.e., transgender and gender diverse) are up to 4.05 times more likely to be diagnosed.
One of the 4th Panzer Army commanders, Erich Hoepner, was executed for his role in the 20 July plot. Following the end of the war, one of the 4th Panzer Army former commanders, Hermann Hoth, was tried in the High Command Trial, one of the Subsequent Nuremberg Trials. Explaining his harsh measures against Jews and other civilians, he claimed that "it was a matter of common knowledge in Russia that it was the Jew in particular who participated in a very large extent in sabotage, espionage, etc." Hoth was found guilty of war crimes and crimes against humanity. On 27 October 1948, he was sentenced to 15 years in prison. In January 1951, the sentence was reviewed with no changes. Hoth was released on parole in 1954; his sentence was reduced to time served in 1957. None of the other commanders ever faced charges.
In ibritumomab tiuxetan, the chelator tiuxetan is a modified version of DTPA whose carbon backbone contains an isothiocyanatobenzyl and a methyl group. In capromab pendetide and satumomab pendetide, the chelator pendetide (GYK-DTPA) is a modified DTPA containing a peptide linker used to connect the chelate to an antibody. Pentetreotide is a modified DTPA attached to a peptide segment. DTPA and derivatives are used to chelate gadolinium to form an MRI contrast agent, such as Magnevist. Technetium-99m is chelated with DTPA for ventilation perfusion (V/Q) scans and radioisotope renography nuclear medicine scans.
Sources: en.wikipedia.org
Cathode: 3 O2 + 6 H2O + 12 e− → 12 OH− Anode: 4 Fe → 4 Fe2+ + 8 e−; 4 Fe2+ → 4 Fe3+ + 4 e− Overall: 4 Fe + 3 O2 + 6 H2O → 4 Fe3+ + 12 OH− → 4 Fe(OH)3 or 4 FeO(OH) + 4 H2O The electrolyte is usually iron(II) sulfate in urban areas (formed when atmospheric sulfur dioxide attacks iron), and salt particles in the atmosphere in seaside areas.
== Academic and professional career == In 1982, Wu began his academic career as assistant professor of Pathology and Laboratory Medicine at the University of Texas Health Science Center in Houston, where he served as Associate and then Director of Clinical Chemistry at Memorial Hermann Hospital. After a decade in Texas, Wu left for a position at Hartford Hospital, where he served as Director of Clinical Chemistry and Professor of Laboratory Medicine at the University of Connecticut Health Center. He also held appointments as Professor of Pathobiology and Chemistry at the University of Connecticut, Storrs. In 2004, Wu joined the faculty at the University of California, San Francisco as Professor of Laboratory Medicine and Director of Clinical Chemistry, Toxicology, and Pharmacogenomics at San Francisco General Hospital.
Proenkephalin (PENK), formerly known as proenkephalin A (since proenkephalin B was renamed prodynorphin), is an endogenous opioid polypeptide hormone which, via proteolyic cleavage, produces the enkephalin peptides met-enkephalin, and to a lesser extent, leu-enkephalin. Upon cleavage, each proenkephalin peptide results in the generation of four copies of Met-enkephalin, two extended copies of met-enkephalin, and one copy of leu-enkephalin. Contrarily, Leu-enkephalin is predominantly synthesized from prodynorphin, which produces three copies of it per cleavage, and no copies of Met-enkephalin. Other endogenous opioid peptides produced by proenkephalin include adrenorphin, amidorphin, BAM-18, BAM-20P, BAM-22P, peptide B, peptide E, and peptide F. The following table lists the peptides that are derived from cleavage of the proenkephalin protein.
=== Aspidosperma quebracho-blanco === Aspidosperma quebracho-blanco is an unrelated tree whose common name is quebracho blanco. It is found in large areas of central South America, particularly the Gran Chaco, where it is often the dominant species in the canopy. It is one of the most widely distributed Argentine arboreal species. Traditionally it was logged for fuel, timber and railway sleepers. While in recent times cattle ranching and soya cultivation have led to considerable habitat loss, and while there is still illegal logging, no shortage of the bark is reported. The tree has not been described as endangered: a few members of the genus Aspidosperma are on the IUCN Red List. but the quebracho blanco species is not one of them.
In surgical praxis, after having emplaced the empty breast implants to the implant pockets, the plastic surgeon then filled each device with saline solution, and, because the required insertion-incisions are short and small, the resultant incision-scars will be smaller and shorter than the surgical scars usual to the long incisions required for inserting pre-filled, silicone-gel implants. When compared to the results achieved with a silicone-gel breast implant, the saline implant can yield acceptable results, of increased breast-size, smoother hemisphere-contour, and realistic texture; yet, it is likelier to cause cosmetic problems, such as the rippling and the wrinkling of the breast-envelope skin, accelerated lower breast pole stretch, and technical problems, such as the presence of the implant being noticeable to the eye and to the touch. The occurrence of such cosmetic problems is likelier in the case of the woman with very little breast tissue, and in the case of the woman who requires post-mastectomy breast reconstruction; thus, the silicone-gel implant is the technically superior prosthetic device for breast augmentation, and for breast reconstruction. In the case of the woman with much breast tissue, for whom sub-muscular emplacement is the recommended surgical approach, saline breast implants can produce an aesthetic result much like that afforded by silicone breast implants. Ultrasound examination and outcome studies have revealed that saline and silicone breast implants look and feel similar.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.